2020년 세계 요도협착 치료 기기 시장 규모는 14억 8,000만 달러에 달했습니다. 이 시장은 2024년부터 2030년까지 예측 기간 동안 7.10%의 성장률을 보이며 2030년에는 22억 3,000만 달러에 달할 것으로 예상됩니다. 요도협착 치료 기기에 대한 수요가 급증하는 주요 이유는 대장암, 전립선암 등 골반 부위의 암 유병률 증가, 암 치료가 요도협착증 형성 확률 증가, 전립선비대증 유병률 증가, 수술적 개입의 합병증으로 요도협착증이 형성될 수 있다는 점, 고령화, 전립선비대증 요도 카테터 사용으로 인한 요도협착을 유발하는 신경인성 방광 등 여러 질환의 발병에 주요한 역할을 하는 노인 인구의 증가, 약물 용출성 비뇨기 풍선 등 제품 개발의 발전은 예측 기간 동안 요도협착 치료 기기 시장의 성장을 촉진할 것으로 예상됩니다. 시장 성장을 견인할 것으로 예상됩니다.
요도협착 치료 기기 시장은 대장암, 전립선암 등 골반 부위에 특화된 다양한 암의 유병률 증가를 원인 중 하나로 꼽으며 제품 수요가 급증하고 있는 것으로 나타났습니다. 세계보건기구(WHO) 데이터에 따르면 2020년 대장암과 직장암은 세계에서 세 번째로 많은 암으로 193만 명이 새로 발병했으며, 같은 WHO의 팩트 시트에 따르면 2020년 전립선암은 세계에서 네 번째로 많은 암으로 141만 명의 신규 환자가 발생했다고 합니다. 요도협착은 전립선암 및 직장암 방사선 치료, 전립선 비대증 및 전립선암 수술, 생식기 및 회음부 외상 등의 합병증으로 발생합니다. 암 치료, 특히 전립선암에 대한 방사선 치료는 치료 부위 주변의 혈관을 감소시킨다는 것이 여러 연구를 통해 입증되었습니다. 또한, 방사선 치료와 외부 방사선 치료를 모두 받은 환자의 경우 요도 협착이 발생할 위험이 더욱 높아지는 것으로 보입니다. 또한, 방사형 전립선 절제술도 요도협착의 발생 가능성을 유의하게 증가시키는 것으로 보고되어 골반 부위의 암 치료가 요도협착을 유발할 수 있음을 시사하고 있습니다. 따라서 골반 부위의 암 유병률 증가는 요도 협착증의 발생률 증가로 이어져 요도협착 치료 기기에 대한 수요를 촉진하고 궁극적으로 예측 기간 동안 요도협착 치료 기기 시장을 주도할 수 있습니다.
이 보고서는 세계 요도협착 치료 기기 시장을 조사하여 시장 개요와 함께 제품 유형별, 협착 위치별, 최종사용자별, 지역별 동향, 시장 진입 기업 개요 등의 정보를 제공합니다.
Urethral Stricture Treatment Devices Market By Product Type (Urethral Dilators, Urethral Stents, Urethral Balloon Dilation Catheters, And Urinary Catheters), By Stricture Location (Anterior And Posterior), By End User (Hospitals, Specialty Clinics, And Others), and by geography is expected to grow at a steady CAGR (forecast period- 2024-2030) owing to increase in probability of urethral stricture formation as a complication of cancer treatment for prostate and colorectal cancers as well as extensive use of urinary catheters
Global urethral stricture treatment devices market was valued at USD 1.48 billion in 2020, growing at a CAGR of 7.10% during the forecast period from 2024 to 2030 to reach USD 2.23 billion by 2030. The demand for urethral stricture treatment devices is witnessing a surge majorly due to the rising prevalence of cancers in the pelvic region such as colorectal and prostate cancers wherein the cancer treatment is linked with increased probability of urethral stricture formation, growing prevalence of benign prostatic hyperplasia in which urethral stricture may form as a complication of surgical interventions, increasing geriatric population wherein aging plays a major role in the development of numerous diseases such as neurogenic bladder leading to the development of urethral strictures sue to extensive use of urinary catheters, and advancements in product development such as drug-eluting urology balloon thereby boosting the growth of the urethral stricture treatment devices market during the forecast period.
Urethral Stricture Treatment Devices Market Dynamics:
The urethral stricture treatment devices market is observing a surge in product demand due to plethora of reasons with one of them being the rising prevalence of various cancers specifically in the pelvic region such as colorectal and prostate cancers. As per the data cited by the World Health Organization (WHO), in 2020, cancer of the colon and rectum were the third-most common cancer type globally and accounted for 1.93 million new cases. In the same factsheet by the WHO, in 2020, prostate cancer was the fourth-most prevalent cancer type globally and accounted for 1.41 million new cases. Urethral strictures have been associated as a complication of radiation treatment for prostate and rectal cancers, surgery for an enlarged prostate or prostate cancer, or trauma to the genitals or perineum. It has been established in various studies that radiation therapy for cancer treatment, particularly prostate cancer, leads to reduced vascularity around the treatment area. Furthermore, the risk for developing urethral strictures appear to enhance further in patient receiving both the brachytherapy and external beam radiation therapy. Additionally, it has also been reported that radial prostatectomy also significantly increases the chances of the formation of urethral strictures thereby indicating that treatment of cancers in the pelvic region may result in the formation of urethral strictures. Therefore, the rising prevalence of cancers in the pelvic region may result in the increased incidence of urethral strictures which in turn may drive the demand for urethral strictures treatment devices ultimately driving the urethral strictures treatment devices market during the forecast period.
Another important aspect driving the demand for urethral stricture treatment devices market is the rising geriatric population. As per the statistics quoted by the World Health Organization in their Decade of Healthy Ageing (2020-2030) Report, it has been estimated that people in the age bracket of 60 years and older will account for 34% more share in the total population, increasing from one billion in 2019 to 1.4 billion by 2030. The report further mentioned that by 2050, the global elderly population is expected to reach 2.1 billion. Aging is considered as one of the key risk factors that heavily contributes in the development of various indications such as benign prostatic hyperplasia (BPH), neurogenic bladder among other indications. BPH is most commonly treated by simple prostatectomies and transurethral resection of the prostate wherein urethral strictures are reported as a common complication. Furthermore, the increasing prevalence of neurogenic bladder also results in the increased chances of urethral stricture formation due to trauma or injury caused with the extensive use of urinary catheters. Therefore, the rising geriatric population is expected to result in increasing prevalence of diseases such as BPH where the treatment may result in the formation of urethral strictures, thereby bolstering the growth of the urethral stricture treatment devices in coming years.
However, device-related complications and the availability of alternative surgical approaches such as urethroplasty may be limiting factors for the growth of the urethral stricture treatment devices market.
Besides the above-mentioned factors, the urethral stricture treatment devices market registered a period of decline in revenue generation due to the COVID-19 pandemic. The lockdown implemented by various governments worldwide to contain the spread of the COVID-19 infection resulted in postponement of outpatient consultations and various surgeries across all medical specialties specifically impacting elective procedures. This led to a considerable reduction in the demand for urethral stricture treatment procedures were classified under non-emergency procedures. Furthermore, the implementation of global lockdown in also impacted the procurement and supply chain. Although, the regulatory approval of various COVID-19 vaccines and mass vaccination programs have been crucial in reestablishing the demand for urethral stricture treatment devices, thereby presenting a positive growth environment for the urethral stricture treatment devices market during the forecast period.
Urethral Stricture Treatment Devices Market Segment Analysis:
Urethral Stricture Treatment Devices Market by Product Type (Urethral Dilators, Urethral Stents, Urethral Balloon Dilation Catheters, and Urinary Catheters), by Stricture Location (Anterior and Posterior), by End User (Hospitals, Specialty Clinics, and Others), and by Geography (North America, Europe, Asia-Pacific, and Rest of the World).
In the product segment of the urethral stricture treatment devices market, the urethral balloon dilation catheters category is expected to register a healthy CAGR in the urethral stricture treatment devices market during the forecast period. This can be attributed to the advantages offered by these devices over their counterparts. Balloon dilation is a well-tolerated, safe, office-based procedure that offers multiple advantages over sequential rigid dilation and internal urethrotomy. It is associated with minimal complications. Furthermore, urethral balloon dilation is considered as a minimally invasive technique that has the potential advantage of being less morbid and is technically less challenging to perform. It is also considered to be less traumatic than sequential rigid dilatation.
Owing to the advantages associated with the urethral balloon dilation catheters, there have been an increase in the development of newer products aimed at treating urethral strictures. For instance, in December 2022, Urotronic received the regulatory approval from the US Food and Drug Administration for their product- Optilume, durg-coated urology balloon, which elutes a highly lipophilic drug, paclitaxel that limits hyperactive cell proliferation and the fibrotic scar tissue generation that results in stricture recurrence.
Therefore, the advantages associated with urethral balloon dilation and the innovation in product development are expected to boost the demand for this product category thereby ultimately propelling the market for urethral balloon dilation catheters during the forecast period.
North America is expected to dominate the overall Urethral Stricture Treatment Devices Market:
Among all the regions, North America is estimated to account for the largest share in the urethral stricture treatment devices market. This domination is due to the increase in prevalence of sexually transmitted diseases, increasing prevalence of cancers in the region. Furthermore, the rising geriatric population as well as growing cases of obesity in the US population are also expected to result in growing number of urethral strictures in the North American region. Additionally, extensive research and development activities pertaining to product development and conducive regulatory environment further helps product manufacturers to generate more revenue from the region.
One of the key driving factors of the United States urethral stricture treatment devices market is the interplay of various factors in the country. For instance, as per the data cited by the Centers for Disease Control and Prevention (2023), in 2019, 2.6 million cases of sexually transmitted diseases were reported in the country registering a 6th-consecutive year increase from 1.4 million in 2014. STDs like gonorrhea are reported to cause infection and inflammation in the urethra, leading to scarring and stricture. Some chronic inflammatory skin conditions like lichen sclerosus can also cause urethral strictures. Therefore, the presence of large patient population suffering from sexually transmitted diseases correlates to the presence of a potential patient population that may resort to using urethral stricture devices as a treatment method, thus driving the product demand in the nation.
Moreover, increasing obese population is also expected to drive the demand for urethral stricture treatment devices in the country. For instance, as per the data provided by the CDC (2023), in 2017-2018, the obesity prevalence in the country was 42.4%. Obesity has been associated with increased mean urethral stricture length in obese patients compared to patients with a normal body-mass index.
Thus, the interplay of all the aforementioned factors are likely to fuel the market growth of urethral stricture treatment devices in the United States during the forecast period.
Urethral Stricture Treatment Devices Market Key Players:
Some of the key market players operating in the urethral stricture treatment devices market includes Boston Scientific Corporation, Laborie, Cook, Teleflex Incorporated, B. Braun Melsungen AG, Allium Ltd., Pnn Medical A/S, Zhejiang ChuangXiang Medical Technology co., LTH, UROMED Kurt Drews KG, Med pro Medical B.V., BD, Cardinal Health. Coloplast, ConvaTec Inc, BACTIGUARD AB and others.
Recent Developmental Activities in Urethral Stricture Treatment Devices Market:
In December 2022, Urotronic received the regulatory approval from the US Food and Drug Administration for their product- Optilume, durg-coated urology balloon, which elutes a highly lipophilic drug, paclitaxel that limits hyperactive cell proliferation and the fibrotic scar tissue generation that results in stricture recurrence.
Key Takeaways from the Urethral Stricture Treatment Devices Market Report Study
Market size analysis for current urethral stricture treatment devices market size (2023), and market forecast for 5 years (2024-2030)
The effect of the COVID-19 pandemic on this market is significant. To capture and analyze suitable indicators, our experts are closely watching the urethral stricture treatment devices market.
Top key product/services/technology developments, merger, acquisition, partnership, joint venture happened for last 3 years
Key companies dominating the global urethral stricture treatment devices market.
Various opportunities available for the other competitor in the urethral stricture treatment devices market space.
What are the top performing segments in 2023? How these segments will perform in 2030.
Which is the top-performing regions and countries in the current urethral stricture treatment devices market scenario?
Which are the regions and countries where companies should have concentrated on opportunities for urethral stricture treatment devices market growth in the coming future?
Target Audience who can be benefited from this Urethral Stricture Treatment Devices Market Report Study
Urethral stricture treatment devices products providers
Research organizations and consulting companies
Urethral stricture treatment device-related organizations, associations, forums, and other alliances
Government and corporate offices
Start-up companies, venture capitalists, and private equity firms
Distributors and Traders dealing in urethral stricture treatment devices
Various End-users who want to know more about the urethral stricture treatment devices market and latest technological developments in the urethral stricture treatment devices market.
Frequently Asked Questions for Urethral Stricture Treatment Devices Market:
A urethral stricture treatment device is a medical device which helps in treating the narrowing of the urethra by opening it up and helping in passage of urine. Urethral dilators, urology balloons, and urethral stents among other interventions.
Global urethral stricture treatment devices market was valued at USD 1.48 billion in 2020, growing at a CAGR of 7.10% during the forecast period from 2024 to 2030 to reach USD 2.23 billion by 2030.
The demand for urethral stricture treatment devices is witnessing a surge majorly due to the rising prevalence of cancers in the pelvic region such as colorectal and prostate cancers wherein the cancer treatment is linked with increased probability of urethral stricture formation, growing prevalence of benign prostatic hyperplasia in which urethral stricture may form as a complication of surgical interventions, increasing geriatric population wherein aging plays a major role in the development of numerous diseases such as neurogenic bladder leading to the development of urethral strictures sue to extensive use of urinary catheters, and advancements in product development such as drug-eluting urology balloon thereby boosting the growth of the urethral stricture treatment devices market during the forecast period.
Some of the key market players operating in the urethral stricture treatment devices market includes Boston Scientific Corporation, Laborie, Cook, Teleflex Incorporated, B. Braun Melsungen AG, Allium Ltd., Pnn Medical A/S, Zhejiang ChuangXiang Medical Technology co., LTH, UROMED Kurt Drews KG, Med pro Medical B.V., BD, Cardinal Health. Coloplast, ConvaTec Inc, BACTIGUARD AB and others.
Among all the regions, North America is estimated to account for the largest share in the urethral stricture treatment devices market. This domination is due to the increase in prevalence of sexually transmitted diseases, increasing prevalence of cancers in the region. Furthermore, the rising geriatric population as well as growing cases of obesity in the US population are also expected to result in growing number of urethral strictures in the North American region. Additionally, extensive research and development activities pertaining to product development and conducive regulatory environment further helps product manufacturers to generate more revenue from the region.